Symbols / TNXP Stock $11.46 -2.13% Tonix Pharmaceuticals Holding Corp.

Healthcare • Biotechnology • United States • NMS
TNXP (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Seth Lederman M.D.
Exch · Country NMS · United States
Market Cap 182.68M
Enterprise Value -1.50M
Income -147.39M
Sales 17.56M
FCF (ttm) -76.73M
Book/sh 19.17
Cash/sh 11.63
Employees 142
Insider 10d —
IPO May 10, 2012
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 0.05
Forward P/E -1.47
PEG —
P/S 10.41
P/B 0.60
P/C —
EV/EBITDA 0.01
EV/Sales -0.09
Quick Ratio 6.57
Current Ratio 6.99
Debt/Eq 0.57
LT Debt/Eq —
EPS (ttm) -14.66
EPS next Y -7.80
EPS Growth —
Revenue Growth 183.20%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-10
Earnings (prior) 2026-05-11
ROA -41.92%
ROE -72.33%
ROIC —
Gross Margin 58.56%
Oper. Margin -6.04%
Profit Margin 0.00%
Shs Outstand 15.94M
Shs Float 15.92M
Insider Own 0.13%
Instit Own 41.42%
Short Float 18.01%
Short Ratio 6.37
Short Interest 2.87M
52W High 69.97
vs 52W High -83.62%
52W Low 10.87
vs 52W Low 5.43%
Beta 1.68
Impl. Vol. 6.25%
Rel Volume 1.17
Avg Volume 454.70K
Volume 530.50K
Target (mean) $46.25
Tgt Median $49.00
Tgt Low $22.00
Tgt High $65.00
# Analysts 4
Recom Strong_buy
Prev Close $11.71
Price $11.46
Change -2.13%
About

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$46.25
Mean price target
2. Current target
$11.63
Latest analyst target
3. DCF / Fair value
$-86.64
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$11.63
Low
$22.00
High
$65.00
Mean
$46.25

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-04 init TD Cowen — → Buy $22
2025-03-20 reit Noble Capital Markets Outperform → Outperform $70
2024-07-22 main Alliance Global Partners Buy → Buy $11
2024-02-28 init Dawson James — → Buy $3
2023-08-01 main Alliance Global Partners Buy → Buy $8
2023-06-02 main Alliance Global Partners Buy → Buy $18
2021-08-31 main Alliance Global Partners Buy → Buy $3
2021-08-11 main Alliance Global Partners Buy → Buy $2
2021-02-25 main Alliance Global Partners Buy → Buy $4
News
RSS: Latest TNXP news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-06-09 LEDERMAN SETH Chief Executive Officer — 5,000 $11.79 $58,950
2026-06-08 STILLWELL RICHARD NEWCOMB Director — 5,000 $11.65 $58,250
2026-03-31 LEDERMAN SETH Chief Executive Officer — 5,000 $12.62 $63,100
2026-03-18 LEDERMAN SETH Chief Executive Officer — 15,000 $14.89 $223,350
2025-12-31 SAENGER BRADLEY Chief Financial Officer — 701 $13.42 $9,407
2025-08-21 TAYLOR CAROLYN E. Director — 418 $36.03 $15,061
2025-08-20 TRECO JAMES Director — 250 $36.00 $9,000
2025-05-15 LEDERMAN SETH Chief Executive Officer — 4,000 $21.55 $86,200
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
13.11
+29.85%
10.09
+29.94%
7.77
0.00
Operating Revenue
13.11
+29.85%
10.09
+29.94%
7.77
0.00
Cost Of Revenue
6.64
-14.49%
7.76
+63.78%
4.74
0.00
Reconciled Cost Of Revenue
6.64
-14.49%
7.76
+63.78%
4.74
0.00
Gross Profit
6.47
+177.67%
2.33
-23.06%
3.03
0.00
Operating Expense
129.16
+66.70%
77.48
-36.18%
121.41
+8.31%
112.09
Research And Development
44.49
+11.29%
39.97
-53.87%
86.66
+5.84%
81.88
Selling General And Administration
87.68
+118.66%
40.10
+15.39%
34.75
+15.02%
30.21
General And Administrative Expense
—
—
34.75
+15.02%
30.21
Other Gand A
—
—
34.75
+15.02%
30.21
Other Operating Expenses
-3.01
-16.11%
-2.59
—
—
Total Expenses
135.80
+59.31%
85.24
-32.43%
126.15
+12.54%
112.09
Operating Income
-122.69
-63.26%
-75.15
+36.52%
-118.38
-5.61%
-112.09
Total Operating Income As Reported
-125.70
+8.05%
-136.70
-15.48%
-118.38
-5.61%
-112.09
EBITDA
-122.01
+2.69%
-125.38
-9.90%
-114.09
-2.93%
-110.84
Normalized EBITDA
-119.92
-65.23%
-72.57
+36.39%
-114.09
-2.93%
-110.84
Reconciled Depreciation
1.93
-43.73%
3.42
-20.27%
4.29
+242.46%
1.25
EBIT
-123.93
+3.78%
-128.80
-8.80%
-118.38
-5.61%
-112.09
Total Unusual Items
-2.09
+96.04%
-52.81
0.00
—
Total Unusual Items Excluding Goodwill
-2.09
+96.04%
-52.81
0.00
—
Special Income Charges
-2.09
+96.45%
-58.96
0.00
—
Other Special Charges
2.09
—
—
—
Write Off
0.00
-100.00%
58.96
0.00
—
Net Income
-124.02
+4.63%
-130.04
-11.47%
-116.66
-5.84%
-110.22
Pretax Income
-124.02
+4.63%
-130.04
-11.47%
-116.66
-5.84%
-110.22
Net Non Operating Interest Income Expense
4.06
+434.74%
-1.21
—
1.87
Interest Expense Non Operating
0.09
-92.79%
1.23
—
—
Net Interest Income
4.06
+434.74%
-1.21
—
1.87
Interest Expense
0.09
-92.79%
1.23
—
—
Interest Income Non Operating
4.15
+18745.45%
0.02
—
1.87
Interest Income
4.15
+18745.45%
0.02
—
1.87
Other Income Expense
-5.39
+89.96%
-53.67
-3216.96%
1.72
-8.06%
1.87
Other Non Operating Income Expenses
-3.29
-280.05%
-0.87
-150.35%
1.72
-8.06%
1.87
Gain On Sale Of Security
—
6.15
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-124.02
+4.63%
-130.04
-11.47%
-116.66
-5.84%
-110.22
Net Income From Continuing Operation Net Minority Interest
-124.02
+4.63%
-130.04
-11.47%
-116.66
-5.84%
-110.22
Net Income From Continuing And Discontinued Operation
-124.02
+4.63%
-130.04
-11.47%
-116.66
-5.84%
-110.22
Net Income Continuous Operations
-124.02
+4.63%
-130.04
-11.47%
-116.66
-5.84%
-110.22
Normalized Income
-121.93
-57.88%
-77.23
+33.80%
-116.66
-5.84%
-110.22
Net Income Common Stockholders
-124.02
+4.63%
-130.04
-11.47%
-116.66
+0.19%
-116.88
Otherunder Preferred Stock Dividend
—
—
—
—
Diluted EPS
-14.57
+91.75%
-176.60
+98.80%
-14,720.25
+77.49%
-65,400.00
Basic EPS
-14.57
+91.75%
-176.60
+98.80%
-14,720.25
+77.49%
-65,400.00
Basic Average Shares
8.51
+1055.90%
0.74
+9191.34%
0.01
+343.73%
0.00
Diluted Average Shares
8.51
+1055.90%
0.74
+9191.34%
0.01
+343.73%
0.00
Diluted NI Availto Com Stockholders
-124.02
+4.63%
-130.04
-11.47%
-116.66
+0.19%
-116.88
Preferred Stock Dividends
—
—
—
6.66
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
277.17
+70.16%
162.89
+5.46%
154.46
-31.56%
225.69
Current Assets
228.88
+92.33%
119.00
+149.12%
47.77
-63.47%
130.78
Cash Cash Equivalents And Short Term Investments
207.64
+110.21%
98.78
+295.93%
24.95
-79.25%
120.23
Cash And Cash Equivalents
207.64
+110.21%
98.78
+295.93%
24.95
-79.25%
120.23
Receivables
10.32
+19.34%
8.65
+41.72%
6.10
-24.12%
8.04
Accounts Receivable
6.27
+70.27%
3.68
0.00
—
Other Receivables
3.48
-17.44%
4.22
-8.04%
4.59
-42.93%
8.04
Taxes Receivable
0.57
+0.18%
0.56
—
—
Accrued Interest Receivable
0.00
-100.00%
0.18
-88.10%
1.51
0.00
Inventory
7.01
-16.59%
8.41
-40.57%
14.15
0.00
Raw Materials
2.51
-18.40%
3.07
-14.95%
3.61
0.00
Work In Process
1.37
+543.19%
0.21
-91.61%
2.54
0.00
Finished Goods
2.14
-58.29%
5.12
-31.58%
7.49
0.00
Prepaid Assets
—
—
1.66
+29.88%
1.27
Other Current Assets
3.90
+23.19%
3.17
+23.31%
2.57
+2.59%
2.50
Total Non Current Assets
48.30
+10.04%
43.89
-58.86%
106.69
+12.41%
94.91
Net PPE
46.00
+7.43%
42.82
-54.86%
94.85
+0.34%
94.53
Gross PPE
52.02
+10.89%
46.91
-53.19%
100.21
+4.19%
96.18
Accumulated Depreciation
-6.02
-46.99%
-4.10
+23.59%
-5.36
-224.38%
-1.65
Land And Improvements
8.32
+0.00%
8.32
-0.25%
8.34
+3.05%
8.09
Buildings And Improvements
25.10
+2.42%
24.50
-63.29%
66.75
+1.68%
65.64
Machinery Furniture Equipment
2.01
+46.90%
1.37
-42.05%
2.37
+24.99%
1.89
Construction In Progress
—
—
0.00
-100.00%
1.37
Other Properties
16.39
+29.19%
12.69
-44.17%
22.73
+18.65%
19.16
Leases
0.20
+497.06%
0.03
+0.00%
0.03
+0.00%
0.03
Goodwill And Other Intangible Assets
0.12
+0.00%
0.12
-98.88%
10.71
+8823.33%
0.12
Goodwill
—
0.00
-100.00%
0.96
0.00
Other Intangible Assets
0.12
+0.00%
0.12
-98.77%
9.74
+8019.17%
0.12
Non Current Prepaid Assets
—
—
—
—
Other Non Current Assets
2.17
+128.71%
0.95
-15.77%
1.13
+327.65%
0.26
Total Liabilities Net Minority Interest
32.02
+37.24%
23.33
-52.32%
48.93
+164.38%
18.51
Current Liabilities
30.84
+68.44%
18.31
-3.06%
18.88
+3.87%
18.18
Payables And Accrued Expenses
16.02
+95.31%
8.20
+9.02%
7.53
-26.02%
10.17
Payables
8.11
+78.49%
4.55
+20.20%
3.78
-53.12%
8.07
Accounts Payable
8.11
+78.49%
4.55
+20.20%
3.78
-53.12%
8.07
Current Accrued Expenses
7.91
+116.21%
3.66
-2.27%
3.74
+77.98%
2.10
Pensionand Other Post Retirement Benefit Plans Current
6.14
+36.65%
4.50
+3.10%
4.36
+19.64%
3.65
Current Debt And Capital Lease Obligation
0.12
-95.96%
3.09
+18.09%
2.62
+506.48%
0.43
Current Capital Lease Obligation
0.12
-54.38%
0.27
+1.48%
0.27
-37.50%
0.43
Current Deferred Liabilities
3.42
+88.60%
1.82
-39.06%
2.98
-8.95%
3.27
Current Deferred Revenue
3.42
+88.60%
1.82
-39.06%
2.98
-8.95%
3.27
Other Current Liabilities
5.12
+634.58%
0.70
-50.14%
1.40
+112.14%
0.66
Total Non Current Liabilities Net Minority Interest
1.18
-76.44%
5.03
-83.28%
30.05
+9060.98%
0.33
Long Term Debt And Capital Lease Obligation
1.18
-76.44%
5.03
-30.14%
7.19
+2092.99%
0.33
Long Term Debt
—
4.67
-28.87%
6.56
—
Long Term Capital Lease Obligation
1.18
+230.73%
0.36
-43.35%
0.63
+92.68%
0.33
Stockholders Equity
245.15
+75.66%
139.56
+32.25%
105.53
-49.07%
207.18
Common Stock Equity
245.15
+75.66%
139.56
+32.25%
105.53
-49.07%
207.18
Capital Stock
0.01
+225.00%
0.00
0.00
-100.00%
0.01
Common Stock
0.01
+225.00%
0.00
0.00
-100.00%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
12.79
+191.57%
4.39
+23844.58%
0.02
+379.13%
0.00
Ordinary Shares Number
12.79
+191.57%
4.39
+23844.58%
0.02
+379.13%
0.00
Additional Paid In Capital
1,100.14
+26.38%
870.50
+23.23%
706.41
+4.29%
677.38
Retained Earnings
-854.72
-16.97%
-730.69
-21.65%
-600.66
-27.79%
-470.04
Gains Losses Not Affecting Retained Earnings
-0.29
-13.33%
-0.26
-9.91%
-0.23
-38.92%
-0.17
Other Equity Adjustments
-0.29
-13.33%
-0.26
-9.91%
-0.23
-38.92%
-0.17
Total Equity Gross Minority Interest
245.15
+75.66%
139.56
+32.25%
105.53
-49.07%
207.18
Total Capitalization
245.15
+69.98%
144.22
+28.67%
112.09
-45.90%
207.18
Working Capital
198.04
+96.67%
100.69
+248.62%
28.88
-74.35%
112.60
Invested Capital
245.15
+69.98%
144.22
+28.67%
112.09
-45.90%
207.18
Total Debt
1.31
-83.88%
8.12
-17.26%
9.81
+1191.18%
0.76
Capital Lease Obligations
1.31
+107.12%
0.63
-29.93%
0.90
+18.68%
0.76
Net Tangible Assets
245.03
+75.73%
139.44
+47.06%
94.82
-54.21%
207.06
Tangible Book Value
245.03
+75.73%
139.44
+47.06%
94.82
-54.21%
207.06
Derivative Product Liabilities
—
0.00
-100.00%
22.86
0.00
Inventories Adjustments Allowances
—
—
-0.02
0.00
Other Inventories
1.00
—
0.51
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-99.84
-63.88%
-60.92
+40.27%
-102.00
-4.03%
-98.05
Cash Flow From Continuing Operating Activities
-99.84
-63.88%
-60.92
+40.27%
-102.00
-4.03%
-98.05
Net Income From Continuing Operations
-124.02
+4.63%
-130.04
-11.47%
-116.66
-5.84%
-110.22
Depreciation Amortization Depletion
1.93
-43.73%
3.42
-20.27%
4.29
+242.46%
1.25
Depreciation And Amortization
1.93
-43.73%
3.42
-20.27%
4.29
+242.46%
1.25
Other Non Cash Items
4.90
+483.10%
0.84
-6.98%
0.90
—
Stock Based Compensation
6.02
+25.93%
4.78
-48.49%
9.28
-15.02%
10.91
Asset Impairment Charge
0.70
-98.84%
60.45
0.00
—
Operating Gains Losses
2.09
+134.02%
-6.15
-2882.81%
0.22
—
Gain Loss On Investment Securities
—
-6.15
-2273.14%
0.28
—
Gain Loss On Sale Of PPE
—
0.00
+100.00%
-0.06
0.00
Change In Working Capital
8.54
+47.97%
5.78
+16600.00%
-0.04
-1650.00%
-0.00
Change In Receivables
-2.62
+28.89%
-3.68
0.00
—
Changes In Account Receivables
-2.62
+28.89%
-3.68
0.00
—
Change In Inventory
1.73
-53.86%
3.74
+6032.79%
0.06
0.00
Change In Prepaid Assets
-3.16
-187.49%
3.61
+129.69%
1.57
+1059.15%
-0.16
Change In Payables And Accrued Expense
12.90
+509.45%
2.12
+224.24%
-1.70
-1165.00%
0.16
Change In Accrued Expense
9.91
+732.61%
1.19
-33.37%
1.79
+48.22%
1.21
Change In Payable
2.99
+222.98%
0.93
+126.56%
-3.49
-233.97%
-1.04
Change In Account Payable
2.99
+222.98%
0.93
+126.56%
-3.49
-233.97%
-1.04
Change In Other Working Capital
—
—
—
0.00
Change In Other Current Liabilities
-0.30
-2230.77%
-0.01
-137.14%
0.04
+1650.00%
0.00
Investing Cash Flow
-4.53
-3673.33%
-0.12
+99.59%
-29.07
+39.62%
-48.15
Cash Flow From Continuing Investing Activities
-4.53
-3673.33%
-0.12
+99.59%
-29.07
+39.62%
-48.15
Net PPE Purchase And Sale
-3.37
-2707.50%
-0.12
+98.26%
-6.90
+85.68%
-48.15
Purchase Of PPE
-3.37
-2707.50%
-0.12
+98.48%
-7.89
+83.60%
-48.15
Sale Of PPE
—
0.00
-100.00%
1.00
0.00
Capital Expenditure
-3.37
-2707.50%
-0.12
+98.48%
-7.89
+83.60%
-48.15
Net Business Purchase And Sale
—
0.00
+100.00%
-22.17
0.00
Purchase Of Business
—
0.00
+100.00%
-22.17
0.00
Net Other Investing Changes
-1.16
—
—
—
Financing Cash Flow
214.53
+59.06%
134.87
+269.34%
36.52
-58.43%
87.84
Cash Flow From Continuing Financing Activities
214.53
+59.06%
134.87
+269.34%
36.52
-58.43%
87.84
Net Issuance Payments Of Debt
-9.65
-310.64%
-2.35
-126.28%
8.94
0.00
Issuance Of Debt
—
0.00
-100.00%
8.94
0.00
Repayment Of Debt
-9.65
-310.64%
-2.35
0.00
—
Long Term Debt Issuance
—
0.00
-100.00%
8.94
0.00
Long Term Debt Payments
-9.65
-310.64%
-2.35
0.00
—
Net Long Term Debt Issuance
-9.65
-310.64%
-2.35
-126.28%
8.94
0.00
Net Common Stock Issuance
224.18
+59.91%
140.19
+2718.56%
4.97
-94.73%
94.46
Common Stock Payments
-13.76
0.00
+100.00%
-13.96
0.00
Repurchase Of Capital Stock
-13.76
0.00
+100.00%
-13.96
+70.44%
-47.25
Proceeds From Stock Option Exercised
0.00
-100.00%
0.03
-6.90%
0.03
-27.50%
0.04
Net Other Financing Charges
—
-3.00
-113.29%
22.57
—
Changes In Cash
110.16
+49.21%
73.83
+178.08%
-94.56
-62.03%
-58.36
Effect Of Exchange Rate Changes
-0.03
-875.00%
0.00
+106.15%
-0.07
+12.16%
-0.07
Beginning Cash Position
99.68
+285.62%
25.85
-78.54%
120.47
-32.66%
178.90
End Cash Position
209.81
+110.48%
99.68
+285.62%
25.85
-78.54%
120.47
Free Cash Flow
-103.21
-69.08%
-61.05
+44.45%
-109.90
+24.83%
-146.20
Interest Paid Supplemental Data
0.09
-92.79%
1.23
+1302.27%
0.09
—
Common Stock Issuance
237.94
+69.72%
140.19
+640.24%
18.94
-79.95%
94.46
Issuance Of Capital Stock
237.94
+69.72%
140.19
+640.24%
18.94
-85.98%
135.05
Net Preferred Stock Issuance
—
0.00
0.00
+100.00%
-6.66
Preferred Stock Issuance
—
—
0.00
-100.00%
40.59
Preferred Stock Payments
—
0.00
0.00
+100.00%
-47.25
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category